{"id":"pneumo23-pneumovax","safety":{"commonSideEffects":[{"rate":"5–10%","effect":"Injection site erythema or induration"},{"rate":"10–20%","effect":"Injection site pain or soreness"},{"rate":"1–5%","effect":"Fever"},{"rate":"1–3%","effect":"Myalgia or arthralgia"},{"rate":"1–3%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from 23 different pneumococcal serotypes conjugated to a carrier protein or presented as a polyvalent formulation. Upon administration, these antigens trigger B-cell and T-cell responses, leading to the production of opsonizing antibodies that enhance phagocytosis and clearance of pneumococcal bacteria. This provides protection against invasive pneumococcal disease including pneumonia, bacteremia, and meningitis.","oneSentence":"Pneumo23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:14.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years"},{"name":"Prevention of pneumococcal otitis media and sinusitis"}]},"trialDetails":[{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT00339157","phase":"PHASE2, PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":"Systemic-Onset Juvenile Idiopathic Arthritis","enrollment":24},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT05183854","phase":"PHASE2","title":"Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT05417165","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2023-09-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":80},{"nctId":"NCT05815264","phase":"PHASE1","title":"Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2020-09-07","conditions":"Pneumonia","enrollment":144},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT01351896","phase":"PHASE2","title":"Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-02","conditions":"Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":49},{"nctId":"NCT00611663","phase":"PHASE2, PHASE3","title":"Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-05","conditions":"Lupus Erythematosus, Systemic","enrollment":47},{"nctId":"NCT02126384","phase":"NA","title":"Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-11-18","conditions":"Pneumococcal Diseases","enrollment":9},{"nctId":"NCT07142057","phase":"","title":"An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-09-01","conditions":"LUNG CANCER","enrollment":500},{"nctId":"NCT03104075","phase":"PHASE4","title":"Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"The Jackson Laboratory","startDate":"2017-04-17","conditions":"Pneumonia, Aging","enrollment":40},{"nctId":"NCT06271681","phase":"PHASE4","title":"Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Sierra Nevada Health Care System","startDate":"2026-01-01","conditions":"Pneumococcal Vaccines, Immunosuppression","enrollment":45},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT07071701","phase":"","title":"A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-02","conditions":"Pneumococcal Infectious Disease","enrollment":19267},{"nctId":"NCT04460235","phase":"PHASE4","title":"Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-09-07","conditions":"Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin","enrollment":160},{"nctId":"NCT05827874","phase":"PHASE1","title":"A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-12","conditions":"Healthy","enrollment":32},{"nctId":"NCT05028634","phase":"PHASE3","title":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-11-11","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT06678607","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older","status":"COMPLETED","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2023-11-19","conditions":"Pneumococcal Infectious Disease","enrollment":240},{"nctId":"NCT04875533","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-14","conditions":"Pneumococcal Disease","enrollment":1425},{"nctId":"NCT05420961","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-12","conditions":"Pneumonia, Pneumococcal","enrollment":717},{"nctId":"NCT05633992","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-01-10","conditions":"Pneumococcal Disease","enrollment":450},{"nctId":"NCT05464420","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-08-12","conditions":"Pneumococcal Disease","enrollment":2162},{"nctId":"NCT02429531","phase":"PHASE4","title":"Polysaccharide Antibody Response Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-10","conditions":"Specific Polysaccharide Antibody Deficiency","enrollment":200},{"nctId":"NCT06314867","phase":"PHASE3","title":"Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-01-30","conditions":"Healthy Volunteers","enrollment":990},{"nctId":"NCT03803202","phase":"PHASE1, PHASE2","title":"A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-01-24","conditions":"Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease","enrollment":630},{"nctId":"NCT04481243","phase":"PHASE4","title":"A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-04-30","conditions":"Type 1 Diabetes","enrollment":29},{"nctId":"NCT04054752","phase":"PHASE1","title":"Vaccine Response With NT-I7","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-30","conditions":"Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma","enrollment":""},{"nctId":"NCT04665050","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-04","conditions":"Pneumococcal Infection","enrollment":102},{"nctId":"NCT06044077","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People","status":"RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2023-09-08","conditions":"Pneumococcal Disease","enrollment":1920},{"nctId":"NCT02255227","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-04-13","conditions":"Infections, Pneumococcal, Bowel Diseases, Inflammatory","enrollment":104},{"nctId":"NCT05316831","phase":"PHASE4","title":"Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2019-01-01","conditions":"CLL, Vaccine Response","enrollment":77},{"nctId":"NCT03762824","phase":"PHASE4","title":"Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-06-14","conditions":"Rheumatoid Arthritis, Systemic Lupus, Sjögren Syndrome","enrollment":300},{"nctId":"NCT05346302","phase":"EARLY_PHASE1","title":"Persistent Readiness Through Early Prediction Immunization Study","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2022-02-08","conditions":"Inflammatory Response","enrollment":249},{"nctId":"NCT05481801","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)","status":"COMPLETED","sponsor":"Castilla-La Mancha Health Service","startDate":"2022-09-01","conditions":"Type 1 Diabetes","enrollment":300},{"nctId":"NCT04168190","phase":"PHASE1, PHASE2","title":"A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-06","conditions":"Pneumonia, Pneumococcal","enrollment":600},{"nctId":"NCT02274415","phase":"PHASE2","title":"Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-09-16","conditions":"Invasive Pneumococcal Infections, Sickle Cells Disease","enrollment":116},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT04265911","phase":"PHASE1","title":"Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects","status":"COMPLETED","sponsor":"Affinivax, Inc.","startDate":"2020-02-19","conditions":"Healthy Volunteers","enrollment":126},{"nctId":"NCT04953325","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-09","conditions":"COVID-19","enrollment":270},{"nctId":"NCT00788151","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09-26","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":300},{"nctId":"NCT05163834","phase":"PHASE1","title":"Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV","status":"COMPLETED","sponsor":"argenx","startDate":"2021-11-17","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT04700618","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-21","conditions":"Vaccination","enrollment":330},{"nctId":"NCT04701788","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-30","conditions":"Vaccination","enrollment":331},{"nctId":"NCT02547493","phase":"NA","title":"Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2016-03-03","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT03760146","phase":"PHASE3","title":"Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-12-12","conditions":"Pneumococcal Disease","enrollment":3902},{"nctId":"NCT00427895","phase":"PHASE3","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02-27","conditions":"Pneumococcal Infections","enrollment":2141},{"nctId":"NCT03260790","phase":"PHASE4","title":"Pneumococcal Vaccines in Patients With Asthma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-10-01","conditions":"Asthma","enrollment":17},{"nctId":"NCT02279589","phase":"PHASE2","title":"Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-12-04","conditions":"Pneumococcal Infection","enrollment":60},{"nctId":"NCT02045836","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-05","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":865},{"nctId":"NCT04875858","phase":"PHASE4","title":"Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-05-01","conditions":"Pneumococcal Infections","enrollment":254},{"nctId":"NCT03802994","phase":"EARLY_PHASE1","title":"Pneumococcal Conjugate Vaccine in Aging Renal Transplant","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-11-01","conditions":"Renal Transplantation, Aging","enrollment":57},{"nctId":"NCT03835975","phase":"PHASE3","title":"Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-02-12","conditions":"Pneumococcal Disease","enrollment":875},{"nctId":"NCT03478254","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).","status":"COMPLETED","sponsor":"Jesús Moreno Fernández","startDate":"2017-12-01","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT02471014","phase":"","title":"Effect of Obesity on Immune Response to Pneumovax 23","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-12","conditions":"Obesity","enrollment":50},{"nctId":"NCT02012309","phase":"NA","title":"Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"HIV, Pneumococcal Infections, Pneumococcal Vaccines","enrollment":60},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT01942174","phase":"PHASE3","title":"VACcination In Methotrexate Treated Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2013-09-27","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT02654704","phase":"","title":"Vaccination Responses in Young and Older Adults","status":"TERMINATED","sponsor":"Michigan State University","startDate":"2015-11","conditions":"Individuality, Healthy, Asthma","enrollment":61},{"nctId":"NCT02787863","phase":"PHASE4","title":"Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology","status":"COMPLETED","sponsor":"Mikhael Petrovich Kostinov","startDate":"2012-09-06","conditions":"Chronic Obstructive Pulmonary Disease, Asthma, Pneumococcal Infections","enrollment":219},{"nctId":"NCT04278248","phase":"PHASE3","title":"Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2018-01-12","conditions":"Pneumonia, Pneumococcal","enrollment":1940},{"nctId":"NCT01239875","phase":"EARLY_PHASE1","title":"Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-11","conditions":"Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma","enrollment":16},{"nctId":"NCT03313037","phase":"PHASE2","title":"Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-10-10","conditions":"Pneumococcal Infections","enrollment":444},{"nctId":"NCT00307528","phase":"PHASE2","title":"Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01-20","conditions":"Prophylaxis Invasive Pneumococcal Diseases and Pneumonia","enrollment":146},{"nctId":"NCT02573181","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-30","conditions":"Pneumococcal Infections","enrollment":253},{"nctId":"NCT02308540","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2015-01-12","conditions":"Pneumococcal Disease","enrollment":346},{"nctId":"NCT01307449","phase":"NA","title":"Systems Biology of PNEUMOVAX®23 and PREVNAR 13®","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-04","conditions":"Pneumococcal Infection","enrollment":88},{"nctId":"NCT03460730","phase":"PHASE1","title":"Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)","status":"COMPLETED","sponsor":"KEMRI-Wellcome Trust Collaborative Research Program","startDate":"2004-11-04","conditions":"Pneumonia, Pneumococcal","enrollment":100},{"nctId":"NCT02072525","phase":"PHASE4","title":"A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-01","conditions":"Meningococcal","enrollment":359},{"nctId":"NCT00169234","phase":"PHASE1, PHASE2","title":"Pneumococcal Adult-dose Ranging Immunization Study","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2003-05","conditions":"Pneumonia","enrollment":220},{"nctId":"NCT02719379","phase":"PHASE1","title":"Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma","status":"COMPLETED","sponsor":"Rohit Divekar","startDate":"2016-04","conditions":"Asthma","enrollment":60},{"nctId":"NCT00282308","phase":"PHASE2","title":"A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-01-23","conditions":"Rheumatoid Arthritis","enrollment":103},{"nctId":"NCT02538211","phase":"NA","title":"The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-09","conditions":"Rotavirus Infections, Intestinal Bacteria Flora Disturbance, Reaction - Vaccine Nos","enrollment":63},{"nctId":"NCT02097849","phase":"PHASE2","title":"Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-02-28","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":71},{"nctId":"NCT00169507","phase":"PHASE3","title":"Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Prophylaxis Pneumococcal Vaccine","enrollment":100},{"nctId":"NCT00756067","phase":"PHASE1","title":"Evaluation of Pneumococcal Vaccine Formulations in Elderly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-19","conditions":"Infections, Streptococcal","enrollment":168},{"nctId":"NCT00707798","phase":"PHASE1","title":"Evaluation of Pneumococcal Vaccine Formulations in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-30","conditions":"Infections, Streptococcal","enrollment":157},{"nctId":"NCT00327665","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Infections, Streptococcal","enrollment":335},{"nctId":"NCT01654263","phase":"PHASE2","title":"A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10-10","conditions":"Pneumococcal Infection","enrollment":884},{"nctId":"NCT00479323","phase":"PHASE1","title":"Pneumococcal Reference Standard","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-06","conditions":"Pneumococcal Infections","enrollment":250},{"nctId":"NCT02806284","phase":"PHASE2","title":"Pneumococci and Hib Vaccination After Neurotrauma or Neurosurgery","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2001-01","conditions":"Meningitis","enrollment":85},{"nctId":"NCT02097589","phase":"PHASE1","title":"The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-06","conditions":"Healthy Controls","enrollment":33},{"nctId":"NCT02558751","phase":"EARLY_PHASE1","title":"Pneumonia Vaccine in Aging HIV Positive Individuals","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07","conditions":"Pneumococcal Infection","enrollment":51},{"nctId":"NCT02515240","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2010-07","conditions":"Pneumococcal Infection","enrollment":124},{"nctId":"NCT00594347","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-11","conditions":"Streptococcus Pneumoniae","enrollment":339},{"nctId":"NCT00457977","phase":"PHASE3","title":"Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2007-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":181},{"nctId":"NCT00785967","phase":"PHASE3","title":"Immune Responses in Patients Treated With Raltegravir","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00962780","phase":"PHASE3","title":"Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"HIV Infections, Pneumococcal Infections","enrollment":303},{"nctId":"NCT01505855","phase":"PHASE4","title":"Efficacy Study of Pneumococcal Vaccination in Crohn's Disease","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2011-12","conditions":"Crohn's Disease","enrollment":197},{"nctId":"NCT00706550","phase":"NA","title":"Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2008-10","conditions":"HIV Infections","enrollment":107},{"nctId":"NCT02079701","phase":"PHASE4","title":"Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits","status":"COMPLETED","sponsor":"Naval Health Research Center","startDate":"2000-10","conditions":"Pneumonia, Acute Respiratory Disease","enrollment":152723},{"nctId":"NCT02062281","phase":"PHASE4","title":"Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2013-11","conditions":"Pneumococcal Infection, Influenza","enrollment":2225},{"nctId":"NCT01646398","phase":"PHASE3","title":"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine","enrollment":764},{"nctId":"NCT00307008","phase":"PHASE2","title":"Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Streptococcus Pneumoniae Vaccines","enrollment":1198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Antipneumococcal vaccination"],"phase":"phase_3","status":"active","brandName":"Pneumo23 / Pneumovax","genericName":"Pneumo23 / Pneumovax","companyName":"University Hospital, Montpellier","companyId":"university-hospital-montpellier","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pneumo23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years, Prevention of pneumococcal otitis media and sinusitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}